Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Long-acting antimalarials could provide improved prophylaxis and treatment options in the field. Here, Bakshi et al. develop a long-acting injectable atovaquone nanomedicine that prevents malaria infection prophylactically for up to 4 weeks in mice with no evidence for generation of resistant parasi...
Main Authors: | Rahul P. Bakshi, Lee M. Tatham, Alison C. Savage, Abhai K. Tripathi, Godfree Mlambo, Matthew M. Ippolito, Elizabeth Nenortas, Steve P. Rannard, Andrew Owen, Theresa A. Shapiro |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2018-01-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-017-02603-z |
Similar Items
-
Clinically relevant atovaquone-resistant human malaria parasites fail to transmit by mosquito
by: Victoria A. Balta, et al.
Published: (2023-10-01) -
Long-Acting Injectable Statins—Is It Time for a Paradigm Shift?
by: Lee M. Tatham, et al.
Published: (2019-07-01) -
Immune Regulation of <italic toggle="yes">Plasmodium</italic> Is <italic toggle="yes">Anopheles</italic> Species Specific and Infection Intensity Dependent
by: Maria L. Simões, et al.
Published: (2017-11-01) -
Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
by: Ivanovic Jelena, et al.
Published: (2011-05-01) -
Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.
by: McKeage, K, et al.
Published: (2003)